Enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*
Enterprise value of top companies in non-oncology rare disease therapeutics 2017
This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.
Enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*
Value in million U.S. dollars
Biogen69,812
Shire (+predecessors)67,777
Vertex Pharma37,428
Genzyme36,070
Alexion33,114
BioMarin16,261
Jazz Pharma10,141
Bioverativ6,086
Ionis Pharma6,053
bluebird bio5,320
United Therapeutics4,225
Swedish Orphan Biovitrum4,073
Horizon Pharma3,409
Spark Therapeutics3,044
AveXis, Inc.2,671
Amicus Therapeutics2,416
Corcept Therapeutics2,127
Prothena Corporation2,060
Ultragenyx1,970
Intercept Pharma1,624
Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

2017

Region

Worldwide

Survey time period

as of October 2017

Special properties

non-oncology rare disease therapeutics

Method of interview

Online survey

Supplementary notes

* All values are in current U.S. dollars.

Enterprise value of top companies in non-oncology rare disease therapeutics 2017
This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.